The results with VHL-recruiting degraders suggest that in human neurons, specifically in FTD patient iPSC-derived ex vivo neurons, CRBN has higher activity toward tau ubiquitination for proteasome degradation (Silva et al., 2019) and might be a better therapeutic target than VHL. Here, VHL is linked to frontotemporal dementia.